Clinical Trial Detail

NCT ID NCT02892318
Title A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

acute myeloid leukemia

Therapies

Atezolizumab + Guadecitabine

Age Groups: adult senior

No variant requirements are available.